Story
Conagra Shares Drop Despite 46% EPS Beat as Volume Concerns Linger

Summary
The food giant reported first-quarter earnings that significantly surpassed analyst estimates, but its stock declined as investors focused on guidance for falling sales volumes and ongoing competitive pressures.
Conagra Brands (NYSE: CAG) reported a significant first-quarter earnings beat, but its shares fell in trading as investors weighed the positive results against persistent concerns about declining sales volumes and the company's long-term growth trajectory.
The packaged food company's stock was down 3.72% to $13.61 on September 30, despite posting strong quarterly results that appeared to address some market questions.
A Quarter of Contrasts
Conagra announced fiscal first-quarter 2027 earnings per share (EPS) of $0.41, a 46.4% surprise above the consensus analyst estimate of $0.28. Revenue came in at $2.60 billion, nearly identical to the $2.59 billion expected, suggesting a stabilization in sales.
Management's results in the first full quarter under new CEO John Brase also confirmed several strategic moves aimed at shoring up the company's financial health. Conagra reiterated its full-year guidance for free cash flow conversion above 90% and a net leverage target of approximately 4.0x. The company had previously reset its annualized dividend to $0.70 per share, a move that reduces cash outlay by about $335 million per year and removes uncertainty around its sustainability.
Persistent Headwinds Overshadow Beat
Despite the strong bottom-line performance, the market's negative reaction highlights lingering structural challenges. The company's guidance for fiscal 2027 organic net sales remains unchanged at a decline of -1% to -3%, driven by expected mid-single-digit volume drops as a result of inflation-related price increases.
AdInvestors remain focused on several key issues that a single quarter's results cannot resolve:
- Volume Elasticity: The extent to which consumers will pull back on purchasing, particularly in core categories like frozen foods, in response to higher prices is a primary concern.
- Private Label Competition: Store brands continue to gain market share, pressuring established names like Conagra's Birds Eye, Banquet, and Duncan Hines.
- Long-Term Profitability: The company's annual EPS has trended downward from $2.77 in fiscal 2023 to an estimated $1.44 for the current fiscal year 2027, according to analyst projections.
Catalysts on the Horizon
Conagra is moving forward with its AI-driven simplification program, dubbed "Project Catalyst," which is being funded by an increase in capital expenditures to approximately $550 million in fiscal 2027. The initiative targets supply chain, working capital, and operational improvements, though specific financial return targets have not yet been detailed.
Looking ahead, investors will be watching for several key developments. These include a second consecutive earnings beat in the next quarter, more concrete disclosures on cost savings from Project Catalyst, and any signs of improvement in monthly retail sales data. Progress on reducing debt and potential divestitures of non-core businesses were also flagged by management as strategic priorities.
Read next
More on Stocks
Disney Plans Major TV Division Restructuring, Hundreds of Jobs at Risk
The Walt Disney Company is set to overhaul its television business by consolidating divisions, a move expected to result in hundreds of layoffs as part of a broader cost-cutting drive. Disney shares fell more than 3% on the report.

Disney Reportedly Plans Major Restructuring of Television Business
The Walt Disney Company is planning a significant overhaul of its television division that could lead to hundreds of layoffs and the consolidation of units, The Wall Street Journal reported.

Grindr Stock Tumbles Nearly 8% on Concerns Over Telehealth Acquisition
Shares of the social networking app fell sharply as investors reacted negatively to its first major acquisition, a $250 million deal for telehealth provider PurposeMed, citing concerns over dilution, liquidity, and near-term margin pressure.

Raymond James Swaps Healthcare Top Picks for October, Adds UnitedHealth, Xencor, and Calyxt
Investment firm Raymond James has revised its Healthcare Top Picks list for October, adding UnitedHealth, Xencor, and Calyxt while removing three others. The firm cited upcoming catalysts and attractive valuations as key drivers for the changes.